Although both anti-CTLA-4 and anti-PD-1 therapies can block the signaling pathways that inhibit T cell-mediated tumor killing, acting as a type of “release the brakes” mechanism for anti-tumor effects, their mechanisms of action differ. The gene discussed is CTLA4; the disease is neoplasm.